Dean Capital Investments Management LLC Purchases New Holdings in Principia Biopharma Inc (PRNB)

Dean Capital Investments Management LLC purchased a new stake in Principia Biopharma Inc (NASDAQ:PRNB) during the third quarter, according to its most recent filing with the SEC. The fund purchased 18,376 shares of the company’s stock, valued at approximately $537,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PRNB. Victory Capital Management Inc. bought a new stake in shares of Principia Biopharma in the 3rd quarter worth about $234,000. JPMorgan Chase & Co. bought a new stake in shares of Principia Biopharma in the 3rd quarter worth about $442,000. American Century Companies Inc. bought a new stake in shares of Principia Biopharma in the 3rd quarter worth about $2,857,000. BlackRock Inc. bought a new stake in shares of Principia Biopharma in the 3rd quarter worth about $4,368,000. Finally, AXA bought a new stake in shares of Principia Biopharma in the 3rd quarter worth about $4,383,000. Institutional investors own 18.27% of the company’s stock.

In other Principia Biopharma news, major shareholder Leaf Ventures Ii L.P. New bought 270,000 shares of Principia Biopharma stock in a transaction dated Tuesday, September 18th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $4,590,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Srinivas Akkaraju bought 175,000 shares of Principia Biopharma stock in a transaction dated Tuesday, September 18th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $2,975,000.00. The disclosure for this purchase can be found here.

Principia Biopharma stock opened at $26.02 on Friday. Principia Biopharma Inc has a twelve month low of $22.00 and a twelve month high of $36.00.

A number of analysts have recently weighed in on the stock. Robert W. Baird assumed coverage on shares of Principia Biopharma in a report on Tuesday, October 9th. They issued an “outperform” rating on the stock. Leerink Swann assumed coverage on shares of Principia Biopharma in a report on Tuesday, October 9th. They issued an “outperform” rating and a $34.00 target price on the stock. Wells Fargo & Co assumed coverage on shares of Principia Biopharma in a report on Tuesday, October 9th. They issued an “outperform” rating on the stock. Finally, Bank of America assumed coverage on shares of Principia Biopharma in a report on Tuesday, October 9th. They issued a “buy” rating on the stock.

WARNING: “Dean Capital Investments Management LLC Purchases New Holdings in Principia Biopharma Inc (PRNB)” was originally reported by WKRB News and is the property of of WKRB News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2018/11/24/dean-capital-investments-management-llc-purchases-new-holdings-in-principia-biopharma-inc-prnb.html.

About Principia Biopharma

Principia Biopharma Inc, a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome.

Featured Story: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding PRNB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Principia Biopharma Inc (NASDAQ:PRNB).

Institutional Ownership by Quarter for Principia Biopharma (NASDAQ:PRNB)

Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply